Abiopharma

🔍 Dier Mardi (Executive)

Company: MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Report Date: 2026-03-04

Detailed Transactions and Holdings:

• Acquired 5,215 shares of Common Stock (Direct)
  Date: 2026-03-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 14,472.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 646 shares of Common Stock at $431.94 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,826.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 40 shares of Common Stock at $425.08 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,786.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 420 shares of Common Stock at $426.8638 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,366.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 80 shares of Common Stock at $427.845 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,286.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Sold 160 shares of Common Stock at $428.995 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,126.00 | transaction_form_type: 4 | Footnotes: F3, F6
• Sold 40 shares of Common Stock at $429.58 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,086.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 120 shares of Common Stock at $430.9033 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,966.00 | transaction_form_type: 4 | Footnotes: F3, F7
• Sold 116 shares of Common Stock at $432.5559 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,850.00 | transaction_form_type: 4 | Footnotes: F3, F8
• Sold 160 shares of Common Stock at $434.2 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,690.00 | transaction_form_type: 4 | Footnotes: F3, F9
• Sold 80 shares of Common Stock at $435.315 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,610.00 | transaction_form_type: 4 | Footnotes: F3, F10
• Sold 80 shares of Common Stock at $436.69 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,530.00 | transaction_form_type: 4 | Footnotes: F3, F11
• Sold 40 shares of Common Stock at $437.65 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,490.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 6,519 shares of Stock Option (Right to Buy) at $434.8 per share (Derivative)
  Date: 2026-03-04 | Code: A | Expires: 2036-03-04 | equity_swap_involved: 0 | shares_owned_after: 6,519.00 | transaction_form_type: 4 | Footnotes: F12

Footnotes:

• F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.
• F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
• F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive.
• F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive.
• F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive.
• F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive.
• F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive.
• F12: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.